Skip to content
Bored Studies
RecruitingPhase 2

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

Vanda Pharmaceuticals · NCT07090161

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
240
US sites recruiting
18
Study start
September 15, 2025
Record last updated
February 27, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

Being studied: iloperidone; Placebo

Conditions: Hypertension; Uncontrolled Hypertension

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • SiSBP >/= 130 mmHg despite >8 weeks treatment w/ 1 or more antihypertensive therapies

Exclusion Criteria

  • Confirmed Grade 3/severe hypertension (SiSBP >/= 180 mmHg, SiDBP >/= 120 mmHg), unstable cardiac disease, renal insufficiency

Recruiting US locations

Study contacts (from the official record)

  • Vanda Pharmaceuticals, Inc. · 202-734-3400 · clinicaltrials@vandapharma.com
All heart & blood pressure studies in Arizona →
Evaluation of Efficacy and Safety of Iloperidone for the Treatment… (NCT07090161) | Bored Studies